MetaCap

Lexaria Bioscience (LEXX) vs Moleculin Biotech (MBRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lexaria Bioscience is the larger company by market cap ($8.5 million vs $8.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LEXX+16.47%MBRX+1663.50%
+2113%+986%-142%
Oct 7, 20261 yearNov 20, 2026
LEXX+21.39%MBRX+1651.13%
+1964%+916%-132%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LEXX versus MBRX key metrics
MetricLEXXMBRX
Share price$4.03$7.74
Market cap$8.49M$8.22M
1-day change-10.24%-2.40%
P/E ratio (TTM)—0.04
EPS (TTM)$-5.10$179.60
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$705.92K$0
Revenue growth (YoY)+52.05%—
Net income (latest FY)$-11.90M$-33.56M
Gross margin99.61%—
Operating margin-1683.01%—
Net margin-1686.00%—
52-week high$21.60$202.50
52-week low$2.43$3.22
Distance from 52-week high-81.34%-96.18%
Analyst consensusnonestrong_buy
Avg. price target upside+1947.15%+55.04%
Average volume70.52K44.66K
Shares outstanding2.11M1.06M
Employees717
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Lexaria Bioscience

LEXX stock →

Lexaria Bioscience Corp. operates as a biotechnology company.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Moleculin Biotech

MBRX stock →

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

LEXX vs MBRX FAQ

Which is bigger, Lexaria Bioscience or Moleculin Biotech?

Lexaria Bioscience (LEXX) is larger, with a market capitalization of $8.49M compared with $8.22M for Moleculin Biotech (MBRX).

Are Lexaria Bioscience and Moleculin Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons